All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
71 - 80 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Presentation
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Author(s): Calvo et al.
Beamion™ LUNG-1, a Phase Ia/b trial of zongertinib (BI 1810631) in patients with solid tumors: focus on patients with HER2 mutation-positive NSCLC
Author(s): Yoh et al.
Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumors: focus on Asian patients
Author(s): Kuboki et al.
Beamion™ LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
Author(s): Heymach et al.
Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumours: focus on extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
Phase I dose escalation trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients with DLL3+ tumors: focus on SCLC and LCNEC
Author(s): Wermke et al.
Beamion™ LUNG-1, a Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631), in patients with advanced solid tumors with HER2 aberrations
Author(s): Yamamoto et al.
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3/CD3 IgG-like T-cell engager, in patients with DLL3-positive small-cell lung cancer and neuroendocrine carcinoma
Author(s): Wermke et al.
Infographic
DAREON®-7: phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Chauhan et al.